Fidelity Investments
PTPI

Fidelity Investments’s Petros Pharmaceuticals PTPI Stock Holding History

Fidelity Investments’s Portfolio PTPI Stock Details PTPI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q1 		– Sell
-1
Closed -$28 – 5639
2023
Q4 		$28 Buy
+1
New +$36 ﹤0.01% 5129

Other funds holding PTPI

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
TRCT
Tower Research Capital (TRC) New York $3.85B AUM 32.11% 1-Year Est. Return
EL
EMFO LLC Weston, Florida $112M AUM 18.79% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
National Bank of Canada
National Bank of Canada Montreal, Quebec, Canada $112B AUM 31.26% 1-Year Est. Return
NFSG
Newbridge Financial Services Group Boca Raton, Florida $608M AUM 31.28% 1-Year Est. Return
Group One Trading
Group One Trading Chicago, Illinois $52.2B AUM 104.56% 1-Year Est. Return
Osaic Holdings
Osaic Holdings Scottsdale, Arizona $68.3B AUM 20.5% 1-Year Est. Return

Fidelity Investments's PTPI Position: Q1 2024 in Review

Fidelity Investments sold out of Petros Pharmaceuticals (PTPI) in Q1 2024, closing a stake of 1 share — an estimated $28 sold.

Fidelity Investments first reported a position in PTPI in Q4 2023 and held it in 1 quarter. The position peaked at $28 in Q4 2023. 10 funds tracked by Wall St. Rank hold PTPI as of Q1 2024.

  • Fidelity Investments reported no remaining Petros Pharmaceuticals position as of Q1 2024 after selling out during the quarter.
  • Fidelity Investments sold 1 Petros Pharmaceuticals share in Q1 2024, an estimated $28.
  • Fidelity Investments first reported a position in Petros Pharmaceuticals in Q4 2023 and held it in 1 quarter.
  • Fidelity Investments's Petros Pharmaceuticals position peaked at $28 in Q4 2023.
  • 10 funds tracked by Wall St. Rank held Petros Pharmaceuticals as of Q1 2024.

Based on Fidelity Investments's 13F filing for Q1 2024, filed 13 May 2024.